Dernières nouvelles pour Lifecore Biomedical (NASDAQ:LFCR) Stock

Lifecore Biomedical

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.

&nbsp;- $1 million annual run rate with potential for a significant multi-million-dollar scale-up -
KFAR SAVA, Israel, July 7, 2025 /PRNewswire/ -- Silicom Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILC#NASDAQ">SILC</a>), a leading provider of networking and data infrastructure solutions, today announced that it has secured its first Design Win with a US-based provider of Edge-based networking solutions for multi-site businesses. The product is an advanced Edge device that the customer will deploy to enhance the scalability, security and efficiency of its solutions.
Silicom has customized the device to meet the customer's exact specifications, and the customer expects to begin deployment by the end of 2025. Full ramp up is expected to be achieved during 2026, with a projected run rate of approximately $1 million per year.

News

Guidance

Contracts

SILC

Silicom Secures First Design Win With U.S. Edge Networking Provider For Custom Edge Device; Targeting ~$1M Annual Run Rate With Multi-Million-Dollar Scale-Up Potential By 2026

WIIM

EHGO

Eshallgo shares are trading higher after the company announced it secured an exclusive partnership with a top Chinese printer maker.

Management

ATS CEO Andrew Hider To Step Down Effective End Of August, CFO Ryan McLeod To Act As Interim CEO

MBIO

Mustang Bio shares are trading higher after the company was granted FDA Orphan Drug Designation for MB-101 in astrocytomas and glioblastoma.

Mustang Bio Granted FDA Orphan Drug Designation For MB-101 In Astrocytomas And Glioblastoma

JP Morgan analyst Pablo Singzon initiates coverage on Ategrity Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASIC#NYSE">ASIC</a>) with a Overweight rating and announces Price Target of $26.

Price Target

Initiation

Analyst Ratings

ASIC

JP Morgan Initiates Coverage On Ategrity Specialty with Overweight Rating, Announces Price Target of $26

ONDS

Ondas Holdings Announces Partnership Agreement With Klear To Strengthen Financial Sustainability For Growth Companies Across Ondas' Platform

CGTX

Cognition Therapeutics shares are trading higher after the company announced positive Phase 2 data from its Alzheimer's trial for Zervimesine.

Six-time NBA champion and crypto advocate Scottie Pippen has once again shared his <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40850166/nba-legend-scottie-pippen-continues-to-be-bullish-on-bitcoin-after-satoshi-nakamoto-told-h">top crypto picks</a>, placing Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) at the top of his list.
What Happened: Pippen's current <a href="https://x.com/ScottiePippen/status/1941961415558107245">watchlist</a> includes a mix of major altcoins and meme coins, featuring Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), BNB (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>), XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>), Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) and Chainlink (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/link/usd">LINK</a>).
His post on X quickly garnered attention, pulling in nearly 100,000 views. 
Well-known trader MartyParty replied, advising Pippen to focus on Layer 1 tokens listed on CME (like BTC, ETH, SOL, XRP), along with networks supporting regulated stablecoins such as Sui (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">SUI</a>). He added, "everything else is speculation allocation."
Pippen previously sparked buzz in May 2025 when he announced that "<a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45354990/scottie-pippen-declares-altcoin-season-as-ethereum-xrp-dogecoin-shiba-inu-rally">altcoin season is here</a>", citing rallies in ETH, XRP, DOGE, and SHIB.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45354990/scottie-pippen-declares-altcoin-season-as-ethereum-xrp-dogecoin-shiba-inu-rally">Scottie Pippen Declares &#8216;Altcoin Season&#8217; As Ethereum, XRP, Dogecoin, Shiba Inu Rally</a>
Why It Matters: Pippen's renewed endorsement comes amid Bitcoin dominance rising to 65% and prices recently topping $110,000, fueled by strong ETF inflows, corporate demand, and institutional accumulation.
Market commentator Niels <a href="https://x.com/Web3Niels/status/1942148215245058128">outlined</a> a series of bullish catalysts aligning for crypto: 
<ul class="wp-block-list">
<li>The GENIUS Act approval</li>
<li>The $3.3 trillion spending bill passed</li>
<li>Pro-crypto legislation set to be introduced</li>
</ul>
According to Niels, these developments point toward a risk-on macro environment, with the broader crypto market forming a bullish inverse head-and-shoulders pattern, a setup that could drive a massive Q3 rally.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46220570/how-trumps-big-beautiful-bill-could-create-a-big-beautiful-bull-run-for-bitcoin-ethereum-xrp">How Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Could Create A &#8216;Big Beautiful Bull Run&#8217; For Bitcoin, Ethereum, XRP</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$BNB

$BTC

$DOGE

$ETH

$LINK

$SHIB

$SOL

$SUI

$XRP

Scottie Pippen Is Watching Bitcoin, XRP, Dogecoin...And What Else?

OSIS

OSI Systems Receives $17M Order For Cargo And Vehicle Inspection Systems

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

Jasper Therapeutics shares are trading lower after the company reported an 89% response rate in its Urticaria study and will halt the program.

Verticalizes Data Center Ownership to Help Future-Proof Revenue Growth and Enhance Core Profitability
CoreWeave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>), the AI Hyperscaler&#x2122;, and Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>), a leading data center infrastructure provider, today announced that they have signed a definitive agreement under which CoreWeave will acquire Core Scientific in an all-stock transaction. Under the terms of the merger agreement, Core Scientific stockholders will receive 0.1235 newly issued shares of CoreWeave Class A common stock for each share of Core Scientific common stock based on a fixed exchange ratio. Following CoreWeave's successful IPO in March 2025, this acquisition will help CoreWeave verticalize its data center footprint to future-proof revenue growth and enhance profitability. Through this acquisition, CoreWeave will own approximately 1.3 GW of gross power across Core Scientific's national data center footprint1 with an incremental 1 GW+ of potential gross power available for expansion.

Core Scientific, Inc. - Class A Common Stock

CORZ

CRWV

CoreWeave To Acquire Core Scientific In All-Stock Deal To Boost Profitability And Expand Data Center Capacity; Core Scientific Stockholders Will Receive 0.1235 Newly Issued Shares Of CoreWeave Class A Common Stock For Each Share Of Core Scientific Common Stock Based On A Fixed Exchange Ratio

LGPS

LogProstyle shares are trading higher after the company reported a year-over-year increase in FY25 financial results.

Macro Economic Events

Politics

Economics

General

U.S. Treasury Secretary Bessent On U.S. Dollar, Says It's Natural For Currencies To Go Up And Down, Not Out Of The Ordinary; Could Mean Other Currencies Are Strengthening; China's Currency Has Also Depreciated; Will Meet With Chinese Counterpart In Next Few Weeks; Are Things For Us To Do Together If China Wants To Do It Beyond Trade

MRNO

Murano Global Investments shares are trading higher after the company announced it entered into a $500 million equity purchase agreement with Yorkville to enhance its Bitcoin treasury strategy.

U.S. Treasury Secretary Bessent Says We Are Going To Have Several Trade Announcements In Next 48 Hours; I Got A Lot Of New Offers Last Night, On Vietnam, Says 20% Overall Tariffs; Trade Letters Are Pretty Standard Letters; On Treasury Or Fed Jobs, Says I Will Do What The President Wants; On Interest Rates, Says Markets May Be Pricing Economic Fundamentals On Possible Rate Cuts

As of July 7, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Apogee Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>)</h3>
<ul class="wp-block-list">
<li>On July 6, Apogee Therapeutics disclosed positive 16-week data from Phase 2 APEX clinical trial of APG777, its potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis. &#8220;With two out of every three patients treated with APG777 achieving EASI-75 response at Week 16 in the Phase 2 APEX Part A trial, APG777 demonstrated the highest EASI-75 response rate both on a topline and placebo-adjusted basis for any biologic in a global study to date, reinforcing its potential best-in-class profile for patients with moderate-to-severe atopic dermatitis,&#8221; said Michael Henderson, M.D., Chief Executive Officer of Apogee. The company's stock jumped around 18% over the past month and has a 52-week high of $63.50.</li>
<li>RSI Value: 84.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>APGE Price Action: Shares of Apogee Therapeutics gained 7.1% to close at $47.46 on Thursday.</li>
<li>Edge Stock Ratings: 70.45 Momentum score </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/apge"><img loading="lazy" decoding="async" width="422" height="183" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07071721/image-59.png" alt="" class="wp-image-974595" style="width:274px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07071721/image-59.png 422w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07071721/image-59-300x130.png 300w" sizes="(max-width: 422px) 100vw, 422px" /></a></figure>
<h3 class="wp-block-heading">Phibro Animal Health Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>)</h3>
<ul class="wp-block-list">
<li>On June 25, Morgan Stanley analyst Erin Wright maintained Phibro Animal Health with an Equal-Weight rating and raised the price target from $21 to $26. The company's stock gained around 16% over the past month and <a href="https://www.benzinga.com/quote/PAHC">has a 52-week high</a> of $28.49.</li>
<li>RSI Value: 81.7</li>
<li>PAHC Price Action: Shares of Phibro Animal Health gained 0.2% to close at $28.00 on Thursday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>.
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

APGE

PAHC

Top 2 Health Care Stocks That May Plunge This Month

JP Morgan analyst Tien-Tsin Huang initiates coverage on Chime Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHYM#NASDAQ">CHYM</a>) with a Overweight rating and announces Price Target of $40.

CHYM

JP Morgan Initiates Coverage On Chime Financial with Overweight Rating, Announces Price Target of $40

KALV

KalVista Pharmaceuticals shares are trading higher after the company announced it won FDA approval for EKTERLY.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Kaumil Gajrawala upgraded the rating for Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) from Hold to Buy and raised the price target from $194 to $205. Constellation Brands shares closed at $172.32 on Thursday. <a href="https://www.benzinga.com/quote/stz/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Michael Rose upgraded U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) from Outperform to Strong Buy and raised the price target from $51 to $57. U.S. Bancorp shares closed at $47.93 on Thursday. <a href="https://www.benzinga.com/quote/usb/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Julien Dumoulin-Smith upgraded the rating for Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) from Hold to Buy and lifted the price target from&nbsp;$4.9&nbsp;to&nbsp;$7.2. Shoals Technologies shares closed at $5.98 on Thursday. <a href="https://www.benzinga.com/quote/shls/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Ekaterina Knyazkova upgraded Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) from Neutral to Overweight and raised the price target from $25 to $35. Phibro Animal Health shares closed at $28.00 on Thursday. <a href="https://www.benzinga.com/quote/pahc/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying STZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/stz/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07081437/image-63-1024x575.png" alt="" class="wp-image-974676" style="width:607px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07081437/image-63-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07081437/image-63-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07081437/image-63-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07081437/image-63.png 1145w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a> </li>
</ul>
Photo via Shutterstock

Upgrades

OSCR

SHLS

SNDK

VOYG

This Constellation Brands Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

Press Releases

Lifecore Biomedical to Participate in Upcoming Investor and Industry Conferences

Health Care

Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome

Lifecore Biomedical to Report Financial Results for Third Quarter of Fiscal 2025 on April 3, 2025

Earnings

Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update

Biotech

Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference

Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer

Financing

Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale

Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer

Comments

Lifecore Biomedical

Actualités

Dernières nouvelles pour Lifecore Biomedical (NASDAQ:LFCR) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL